Protara Therapeutics' chief medical officer resigns effective June 26, 2026
Leonardo Viana Nicacio's responsibilities will be absorbed by two other executives as the company continues clinical development.
Protara Therapeutics, Inc. disclosed in an 8-K filing dated June 26, 2026 that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities, effective as of June 26, 2026.1
According to the filing, Dr. Nicacio's departing responsibilities will be taken on by Carla Beckham, M.D., who holds the titles of Lead Medical Director and Head of Clinical Development at the company, with supervision continuing under Jacqueline Zummo, Ph.D., Protara's Chief Research & Development Officer.1
The filing was submitted under Item 5.02, covering departures and appointments of officers. It was signed by Patrick Fabbio, Chief Financial Officer, on June 29, 2026.
Protara Therapeutics is incorporated in Delaware and lists its principal offices at 345 Park Avenue South, Third Floor, New York, NY 10010. Its common stock trades under the ticker TARA on The Nasdaq Global Market.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.